Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream

    July 2021 in “ Pharmaceutics ”
    Paul Smith, Wenqing Yao, Stacey Shepard … Swamy Yeleswaram
    Studysummary This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Targeting the Janus Kinase Family in Autoimmune Skin Diseases Frontiers in Immunology · 2019
    2. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
    3. Biomarkers of Alopecia Areata Disease Activity and Response to Corticosteroid Treatment Experimental dermatology · 2015
    4. The Role of Lymphocytes in the Development and Treatment of Alopecia Areata Expert Review of Clinical Immunology · 2015
    5. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    6. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012

    Related research 1

    1. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream Pharmaceutics · 2021